Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2–CCR2 signaling
暂无分享,去创建一个
Y. Shin | Yoon-La Choi | C. Sung | S. Cho | Jinil Han | Hobin Yang | M. Kwon | Hyojin Jeong | Shin Ung Kang | Ha Yeong Chae | S. Kang | H. Chae
[1] Y. Shin,et al. Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer , 2021, Frontiers in Oncology.
[2] M. Kwon. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer , 2019, Archives of Pharmacal Research.
[3] M. Hung,et al. Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.
[4] Z. Fernández-Muñiz,et al. MMP11 expression in intratumoral inflammatory cells in breast cancer , 2019, Histopathology.
[5] Xiaobing Chen,et al. CCL2 promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. , 2019, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[6] G. Murray,et al. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis , 2019, The Journal of pathology.
[7] J. Jonkers,et al. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment , 2018, Cancer and Metastasis Reviews.
[8] E. D. de Vries,et al. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.
[9] Eun-sook Kim,et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. , 2018, Cancer letters.
[10] J. Pollard,et al. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.
[11] Jennifer L. Guerriero. Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.
[12] A. Andicoechea,et al. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes , 2017, Clinical breast cancer.
[13] D. Radisky,et al. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer , 2017, Journal of cellular biochemistry.
[14] Jeong Eon Lee,et al. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer , 2017, Breast Cancer Research and Treatment.
[15] Shun-Fa Yang,et al. MMP-11 promoted the oral cancer migration and FAK/Src activation , 2017, Oncotarget.
[16] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[17] B. Rollins,et al. CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice , 2016, PloS one.
[18] J. Ahn,et al. Gene Expression Profiling of Breast Cancer Brain Metastasis , 2016, Scientific Reports.
[19] M. Yao,et al. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers , 2016, Modern Pathology.
[20] R. Muschel,et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.
[21] S. Yeh,et al. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals , 2015, Oncotarget.
[22] Yanping Zhang,et al. Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression , 2015, BMC Cancer.
[23] Kunwei Shen,et al. Stromal cells in tumor microenvironment and breast cancer , 2012, Cancer and Metastasis Reviews.
[24] Chih-Hsin Tang,et al. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. , 2012, Biochemical pharmacology.
[25] Hongjoo Kim,et al. Diagnostic and Prognostic Relevance of MMP-11 Expression in the Stromal Fibroblast-Like Cells Adjacent to Invasive Ductal Carcinoma of the Breast , 2012, Annals of Surgical Oncology.
[26] M. Furihata,et al. Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance , 2011, Virchows Archiv.
[27] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[28] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[29] A. Mantovani,et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.
[30] Z. Werb,et al. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.
[31] J. Lee,et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival , 2010, BMC Cancer.
[32] M. Moses,et al. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Xiao-Jun Ma,et al. Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.
[34] A. Ben-Baruch,et al. The inflammatory chemokines CCL2 and CCL5 in breast cancer. , 2008, Cancer letters.
[35] L. Matrisian,et al. The other side of MMPs: Protective roles in tumor progression , 2007, Cancer and Metastasis Reviews.
[36] D. Mennerich,et al. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway , 2007, BMC Cancer.
[37] G. Collins. The next generation. , 2006, Scientific American.
[38] Wenmei Li,et al. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. , 2005, Biochemical and biophysical research communications.
[39] L. Haupt,et al. Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines , 2004, BMC Cancer.
[40] L. Hefler,et al. Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer , 2004, Tumor Biology.
[41] Carole Mathelin,et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. , 2003, Cancer research.
[42] M. Shipp,et al. Active stromelysin‐3 (MMP‐11) increases MCF‐7 survival in three‐dimensional Matrigel culture via activation of p42/p44 MAP‐kinase , 2003, International journal of cancer.
[43] C. Sautès-Fridman,et al. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.
[44] H. Saji,et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] M. Barbacid,et al. Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.
[46] Stephen J. Weiss,et al. Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.
[47] S. Weiss,et al. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. , 1994, The Journal of biological chemistry.
[48] P. Chambon,et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.